К содержанию
Dr. Tara EinullaevaMedical oncologist

Cancer glossary

ER and PR on a pathology report: what the percentages mean

What ER and PR mean on a breast cancer IHC report: the 1% cutoff, ‘low positive’ results of 1–10%, why PR matters and how this shapes treatment.

Written and medically reviewed by

Dr. Tara Einullaeva

Medical oncologist, 9 years in practice. Credentials · reviewed 17 October 2026

In short

ER and PR are estrogen and progesterone receptors in breast cancer cells. If ER stains in at least 1% of tumor cells, the cancer is considered hormone-sensitive, and hormone therapy is usually part of the treatment plan.

How it appears in your report

The receptors are measured by immunohistochemistry on tissue from a biopsy or surgery. Typical wording:

  • ‘ER: 95% of tumor cells, strong staining intensity’ — the share of cells with stained nuclei and how strongly they stain.
  • ‘PR: 0%’ — no progesterone receptors.
  • ‘ER: Allred 8’ — the same information as a score: the Allred scale combines the share of stained cells with staining intensity, with 8 as the maximum.
  • ‘ER: low positive (1–10%)’ — a separate category that should come with an explanatory comment.

What it means

ER result Interpretation
under 1% negative
1–10% low positive (ER-low)
over 10% positive

About 3 in 4 breast cancers have at least one of these receptors. A tumor with ER and/or PR is called hormone receptor–positive (HR+).

PR is tested in every invasive breast cancer. The ‘low positive’ category is not used for PR. Russian guidelines use a PR cutoff of 20%, which helps decide which luminal subtype the tumor belongs to.

Does it affect treatment

Yes, a lot. For ER-positive cancer, hormone therapy is considered; when both ER and PR are negative, it does not work. With low-positive ER, the evidence is thinner: ASCO/CAP still support offering hormone therapy, while RUSSCO notes that these tumors respond less well. The final plan combines receptors, HER2, Ki-67 and stage, and your treating doctor makes the call. More detail in the article on IHC in breast cancer.

Questions to ask your doctor

  • What are my ER and PR percentages, and which subtype does that put my tumor in?
  • If ER is 1–10%, how does that change the choice of treatment?
  • Should IHC be repeated on the surgical specimen?

If your report has borderline values, I can review your documents in a consultation.

Sources

  1. ASCO and CAP Release Updated Guideline on Estrogen and Progesterone Testing in Breast Cancer — The ASCO Post (ASCO/CAP), 2020
  2. Breast Cancer Hormone Receptor Status — American Cancer Society, 2026
  3. Практические рекомендации по лекарственному лечению рака молочной железы — RUSSCO, 2023

FAQ

Related terms

This is reference information and not a substitute for medical advice. Your doctor interprets each value in the context of your whole situation.

Related articles

All blog articles